StockNews.AI
VRAX
StockNews.AI
21 days

Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy

1. Virax appointed Dr. Iain Miller as Independent Director effective July 29, 2025. 2. Dr. Miller has over 30 years in diagnostics and MedTech sectors. 3. He will help advance Virax's immune profiling platform and market expansion. 4. Virax focuses on viral disease diagnostics and post-viral condition monitoring. 5. Leadership change may enhance strategic direction and regulatory engagement.

8m saved
Insight
Article

FAQ

Why Bullish?

The appointment of a well-qualified director suggests strategic growth potential, similar to past leadership transitions in biotech enhancing investor confidence.

How important is it?

Dr. Miller’s extensive network and expertise positions Virax for potential advancements in their immune profiling platform, directly impacting stock performance.

Why Long Term?

Dr. Miller's experience may yield benefits over time as Virax progresses in market initiatives and product advancements.

Related Companies

GEBIONHSMHRA
, /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced the appointment of Iain Miller, PhD as an Independent Director to its Board of Directors, effective 29 July 2025. Dr. Miller succeeds Yair Erez, who is stepping down from the Board to focus on other professional endeavours. The Company thanks Mr Erez for his valuable service and contributions. Dr. Miller brings over 30 years of leadership experience across the diagnostics and MedTech sectors, having held senior positions at GE Healthcare, bioMérieux, and Massachusetts General Hospital. He has worked extensively across both the United Kingdom and United States markets and has founded and led four MedTech companies, including Presymptom Health, a UK Ministry of Defence spinout, where he served as Chief Executive Officer. Under his leadership, Presymptom Health developed InfectiClear®, a novel diagnostic for infectious diseases. Dr. Miller has also served on the UK's NICE Technology Appraisal Committee and contributed to innovation programmes at NHS England and the Medicines and Healthcare products Regulatory Agency (MHRA). He holds a PhD in BioEngineering from the University of Strathclyde, an MBA from the University of Edinburgh, and a BSc in Physics & Electronics from the University of Glasgow. He has published extensively on diagnostic innovation. His commercial, technical, and regulatory expertise is expected to contribute meaningfully to Virax's business strategy as the Company works to expand its immune profiling platform into new markets. "We are pleased to welcome Iain Miller, PhD to the Virax Board during this important phase of development," said James Foster, Chief Executive Officer of Virax Biolabs. "His leadership across private and public sector organisations, combined with deep diagnostics expertise and international experience, will be instrumental as we work to advance our immune profiling platform — building on our initial Research-Use-Only (RUO) product rollout and progressing toward IVD development, regulatory engagement, and future market entry." Dr. Miller commented: "I am excited to join the Board of Virax Biolabs at a time of strategic focus and momentum. The Company's immune profiling platform presents a compelling opportunity to enhance how chronic and post-viral conditions are monitored. I look forward to supporting the team in realising this vision." About Virax Biolabs Group Limited. Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation. For more information, please visit www.viraxbiolabs.com. Caution Concerning Forward Looking Statements: This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Virax's Annual Report on Form 20-F for the year ended March 31, 2025. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. SOURCE Virax BioLabs Group Limited WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News